Syneron Medical Ltd
ELOS
ELOS was delisted on the 14th of July, 2017.
1 hedge funds and large institutions have $0 invested in Syneron Medical Ltd in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
75% less funds holding
Funds holding: 4 → 1 (-3)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $34.6M → $0 (-$34.6M)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$31.9M |
| 2 |
LAM
Lapides Asset Management
Greenwich,
Connecticut
|
-$2.04M |
| 3 |
GLAM
Gardner Lewis Asset Management
Chadds Ford,
Pennsylvania
|
-$569K |
ELOS Hedge Fund Activity: Q4 2017 in Review
1 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Syneron Medical Ltd (ELOS) for Q4 2017, worth a combined $0 — down 100% from $34.6M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ELOS and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Brandes Investment Partners, exiting entirely with an estimated $31.9M sold.
- 1 institutional investor held Syneron Medical Ltd (ELOS) as of Q4 2017, down from 4 in Q3 2017.
- Funds reported $0 of Syneron Medical Ltd stock for Q4 2017, down 100% quarter-over-quarter.
- 1 fund opened new Syneron Medical Ltd positions in Q4 2017 and 3 closed out, a net change of -2 holders.
- The largest Syneron Medical Ltd seller in Q4 2017 was Brandes Investment Partners, an estimated $31.9M sold.
Based on aggregated 13F filings for Q4 2017.